drugset / Trial / NCT07135427

Genetic Variation in IgG in Alpha 1 Antitrypsin Deficiency

NCT07135427

NaSingle-groupOpen-labelBasic science

Summary

The goal of this study is to learn whether patients who have a genetic mutation in the genes that cause alpha 1 antitrypsin deficiency also have genetic variation in nearby genes that can increase risk for reduced immune function and respiratory infections. To investigate this hypothesis, we will compare immune responses to the 20-valent pneumococcal conjugate vaccine (PCV20, Pfizer) between participants who have one abnormal copy of the SERPINA1 gene and either no COPD exacerbations, vs those with 2 or more COPD exacerbations in the past year.

Timeline

Start
2025-09-03
Primary completion
2027-03
Completion
2027-06

Drugs

EvaluationDrugModalityDoseRoute
Subject 20-valent pneumococcal conjugate vaccine Vaccine